查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2000570

即时分子诊断市场：依产品类型、技术、应用和最终用户划分－2026-2032年全球市场预测

Point of Care Molecular Diagnostics Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，即时分子诊断市场价值将达到 56.4 亿美元，到 2026 年将成长至 60.6 亿美元，到 2032 年将达到 94.7 亿美元，复合年增长率为 7.66%。

主要市场统计数据
基准年 2025 56.4亿美元
预计年份：2026年 60.6亿美元
预测年份 2032 94.7亿美元
复合年增长率 (%) 7.66%

我们正在透过快速的即时分子诊断来塑造以患者为中心的未来照护模式，从而增强所有医疗保健环境中的临床决策。

即时分子诊断技术透过快速、准确和分散式检测，正在改变患者照护方式。小型化核酸扩增系统和数位连接技术的引入，加速了从集中式检查室到床边检测环境的转变。这种转变使临床医生能够在需要时做出明智的决策，缩短检测结果返回时间，并优化治疗方案。

技术创新和医疗服务模式变革推动了即时分子诊断技术的快速发展。

近年来，卓越的技术进步重塑了即时分子诊断的生态系统。微流体晶片设计和试剂配方的创新显着缩短了检测时间，使关键决策能够在几分钟内而非几小时内做出。同时，携带式硬体和云端资料平台的整合实现了分散式检查与中心检查室网路之间的无缝连接。因此，临床医生现在可以结合患者病历和人群健康指标，立即获得可用的检测结果。

评估 2025 年美国关税措施对即时分子诊断供应链和成本结构的累积影响。

美国将于2025年实施更严格的关税措施，这给即时分子诊断供应商和终端用户带来了新的挑战。仪器及其耗材（如试剂盒和试剂盒）将面临更高的进口关税，这将直接影响其成本结构。为应对这项挑战，製造商正在加快本地化生产并寻求替代采购合同，以降低利润率下降的风险。

按产品类型、技术、应用和最终用户对即时分子诊断市场进行关键細項分析。

对产品类型的全面分析表明，仪器销售仍然是平台普及的基础，这主要得益于设计和便携性方面的持续创新。同时，随着检测项目扩展到多组检测和新型生物标记物，试剂和试剂盒的需求仍然强劲。此外，随着检查室和医疗网路将数据分析和无缝互通性置于独立硬体之上，对软体产品的需求也在不断增长。

阐明影响美洲、欧洲、中东和非洲以及亚太地区引入即时分子诊断的区域趋势。

在美洲，对医疗基础设施的持续投资和有利的法规环境正在加速都市区和农村即时分子诊断技术的应用。联邦政府为加强疫情防范所做的努力已确保了快速检测技术研发的资金支持，而私人医疗网络也在不断扩大门诊和社区健康中心的即时检测能力。

揭示主要企业透过合作、合併和产品开发推动即时分子诊断创新的策略措施。

产业主要企业正优先考虑策略合作和收购，以拓展其即时分子诊断产品组合。大型诊断试剂开发商正与专业试剂生产商合作，共同开发专有检测化学方法并优化供应链。同时，许多公司宣布收购软体分析公司，以提升其分散式检查网路的数据整合能力。

制定切实可行的建议，帮助产业领导者最大限度地利用即时分子诊断机会，增强其竞争优势。

为了掌握分子检测快速成长的需求，产业领导者应投资于支援模组化检测扩充的灵活平台架构。设计能够相容于多种试剂盒的系统，有助于机构快速应对新出现的病原体威胁和不断变化的临床需求。同样重要的是，与试剂生产商建立策略合作伙伴关係，以确保高品质化学反应方法的稳定供应。

详细介绍支持对即时分子诊断进行全面可靠分析的严谨调查方法。

本分析基于严谨的研究框架，结合了对多个地区高阶主管、检查室经理和临床终端使用者的深入访谈。这些对话提供了关于即时分子诊断应用的具体采用者、技术偏好和营运挑战的第一手资料。

概述即时分子诊断在现代医学中的变革潜力和策略挑战。

即时分子诊断融合了技术创新、临床需求和经济可行性。随着平台变得更加紧凑、用户友好和数位化连接，它们有望重新定义诊断流程，并在各种医疗环境中改善患者的治疗效果。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 即时分子诊断市场：依产品类型划分

  • 装置
  • 试剂和试剂盒
  • 软体

第九章 即时分子诊断市场：依技术划分

  • 基因定序基础
  • 杂合反应方法
  • 恒温核酸增幅技术（INAAT）
  • 基于微阵列
  • 基于PCR的

第十章：即时分子诊断市场：依应用领域划分

  • 循环系统
  • 基因检测
    • 携带者筛检
    • 新生儿筛检
    • 产前检查
  • 感染疾病
    • 胃肠道感染疾病
    • 呼吸道感染疾病
    • 性行为感染传染病
    • 热带病
  • 肿瘤学
    • 液态生物检体
    • 突变谱分析
    • 致癌基因检测

第十一章 即时分子诊断市场：以最终用户划分

  • 诊所
  • 检查室
  • 居家医疗环境
  • 医院

第十二章 即时分子诊断市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 即时分子诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 即时分子诊断市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国即时分子诊断市场

第十六章：中国即时分子诊断市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • ACON LABS INC.
  • Becton, Dickinson and Company
  • Binx Health, inc.
  • bioMerieux SA
  • Cardinal Health, Inc.
  • Chembio Diagnostics Inc.
  • Co-Diagnostics, Inc.
  • Danaher Corporation
  • DiaSorin SpA
  • EKF Diagnostics Holdings
  • FHoffmann-La Roche AG
  • Genomadix Inc. by LuminUltra Technologies Ltd.
  • Henry Schein, Inc.
  • Meridian Bioscience, Inc.
  • Novartis AG
  • OraSure Technologies, Inc.
  • Pfizer, Inc.
  • QIAGEN NV
  • Quidel Corporation
  • SD Biosensor
  • Sekisui Diagnostics
  • SHUWEN BIOTECH CO., LTD
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-5A2C6AA669BE

The Point of Care Molecular Diagnostics Market was valued at USD 5.64 billion in 2025 and is projected to grow to USD 6.06 billion in 2026, with a CAGR of 7.66%, reaching USD 9.47 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.64 billion
Estimated Year [2026] USD 6.06 billion
Forecast Year [2032] USD 9.47 billion
CAGR (%) 7.66%

Unlocking the Future of Patient-Centered Care Through Rapid Point of Care Molecular Diagnostics That Enhance Clinical Decision Making Across Healthcare Settings

Point of care molecular diagnostics is transforming the delivery of patient care by enabling rapid, accurate, and decentralized testing. The introduction of miniaturized nucleic acid amplification systems combined with digital connectivity has accelerated the shift from centralized laboratories to bedside testing environments. This transition empowers clinicians to make informed decisions at the point of need, reducing turnaround times and optimizing treatment pathways.

Emerging assay formats leverage isothermal amplification, microfluidics, and integrated cartridge-based workflows to simplify sample preparation and analysis. As a result, healthcare professionals can detect infectious pathogens, genetic mutations, and oncological biomarkers in a fraction of the time required by traditional laboratory platforms. This evolution aligns with the broader trend toward personalized medicine, where diagnostic insights drive targeted therapies and improve clinical outcomes.

Furthermore, evolving reimbursement frameworks and regulatory guidelines have catalyzed the adoption of these devices in diverse care settings. Strategic collaborations between diagnostic developers, healthcare institutions, and digital health companies are fostering interoperability and data integration, creating an ecosystem that supports real-time surveillance and longitudinal patient monitoring.

The lessons learned from global pandemic responses have underscored the critical importance of rapid molecular detection in controlling outbreaks and mitigating public health risks. By deploying portable diagnostic units in field settings and resource-limited environments, stakeholders can identify and contain emerging threats before they spread. Consequently, this capability not only enhances the resilience of healthcare systems but also supports broader public health initiatives aimed at disease surveillance and prevention.

Charting the Rapid Evolution of Point of Care Molecular Diagnostics Driven by Technological Innovation and Shifting Healthcare Delivery Models

Recent years have witnessed remarkable technological advances that are reshaping the point of care molecular diagnostics ecosystem. Innovations in microfluidic chip design and reagent formulation have dramatically reduced assay turnaround times, allowing critical decisions to be made within minutes rather than hours. Simultaneously, the integration of portable hardware with cloud-based data platforms is enabling seamless connectivity between decentralized test sites and central laboratory networks. As a result, clinicians benefit from immediate access to actionable test results alongside patient histories and population health metrics.

Concurrently, the rise of machine learning and artificial intelligence has begun to inform assay interpretation and workflow optimization. Predictive algorithms can now help flag inconsistent assay outputs, standardize quality control, and even suggest differential diagnoses based on molecular signatures. These capabilities not only improve analytical accuracy but also reduce the burden on healthcare professionals, who face increasing pressures related to staffing shortages and rising case volumes.

Regulatory bodies and payers are responding to these shifts by streamlining approval pathways and updating reimbursement codes to reflect the value proposition of rapid molecular assays. In parallel, healthcare systems are exploring value-based care models that incentivize the reduction of hospital stays and readmissions through timely diagnostics. Taken together, these transformative forces are charting a new era in which point of care molecular testing becomes an indispensable component of efficient, patient-centered healthcare delivery.

Assessing the Cumulative Impact of 2025 United States Tariff Measures on Point of Care Molecular Diagnostics Supply Chains and Cost Structures

The imposition of enhanced tariff measures by the United States in 2025 has introduced a new set of challenges for suppliers and end users of point of care molecular diagnostics. Instruments, along with their consumable reagents and kits, are facing increased import duties that directly impact cost structures. In response, manufacturers are accelerating efforts to localize production and secure alternative sourcing agreements, thereby mitigating the risk of margin erosion.

As reagents become subject to higher duties, distributors and diagnostic laboratories are reevaluating inventory strategies and pricing models. Some organizations have begun renegotiating long-term contracts to achieve volume-based discounts or to shift toward vendor-managed inventory solutions that reduce holding costs. Despite these adjustments, smaller clinics and home care providers may experience delayed adoption of new assays due to constrained budgets and tighter procurement cycles.

Yet, amid these headwinds, a silver lining has emerged: renewed interest in domestic supply chain resilience. Stakeholders are exploring partnerships with contract manufacturing organizations and establishing regional distribution hubs to shorten lead times and reduce exposure to global logistics disruptions. Ultimately, the 2025 tariff environment is prompting a strategic realignment across the value chain as industry participants strive to balance cost pressures against the imperative for rapid, reliable molecular diagnostics.

Illuminating Key Segmentation Insights Across Product Types Technologies Applications and End Users in the Point of Care Molecular Diagnostics Market

A comprehensive examination of product categories reveals that instrument sales continue to serve as a cornerstone for platform adoption, driven by ongoing innovations in design and portability. At the same time, reagents and kits are experiencing robust demand as assay menus expand to include multiplex panels and novel biomarkers. Software offerings, meanwhile, are gaining traction as laboratories and care networks prioritize data analytics and seamless interoperability over standalone hardware.

When analyzing technological underpinnings, genetic sequencing-based approaches have begun to penetrate the point of care arena by offering comprehensive genomic insights in near real time. Hybridization-based methods maintain their stronghold in targeted applications, while isothermal nucleic acid amplification technology provides cost-effective, rapid detection in resource-constrained environments. Furthermore, microarray-based solutions are carving out niches in specialized diagnostics, and PCR-based platforms remain the predominant choice for high-sensitivity assays.

In terms of clinical applications, cardiology assays are emerging as a critical tool for identifying acute cardiac events and guiding treatment pathways. Genetic testing has diversified beyond traditional carrier screening to encompass newborn and prenatal diagnostics, delivering actionable information earlier in the patient journey. Infectious disease testing continues to evolve with expanded panels for gastrointestinal, respiratory, sexually transmitted, and tropical pathogens. Oncology has witnessed significant growth in liquid biopsy techniques, mutation profiling, and onco-gene panels that support personalized cancer management.

Finally, end user dynamics underscore a shift toward decentralized models. Clinics are investing in compact systems to deliver same-visit results, whereas diagnostic laboratories reinforce centralized capabilities with point of care extensions. Home care settings are piloting user-friendly devices that enable remote monitoring, and hospitals are integrating molecular diagnostics into emergency and surgical workflows to enhance patient throughput.

Revealing Regional Dynamics Shaping Adoption of Point of Care Molecular Diagnostics Across the Americas Europe Middle East and Africa and Asia-Pacific

In the Americas, sustained investment in healthcare infrastructure and a supportive regulatory environment have accelerated the deployment of point of care molecular diagnostics across both urban and rural settings. Federal initiatives aimed at strengthening pandemic preparedness have unlocked funding for rapid test development, while private healthcare networks continue to expand point of care capabilities within ambulatory care and community health centers.

Across Europe Middle East and Africa, diverse regulatory landscapes present both challenges and opportunities. In Western Europe, harmonized approval processes and robust reimbursement schemes have fostered early adoption of advanced molecular platforms. Meanwhile, in emerging markets, flexible pricing models and public-private partnerships are instrumental in scaling assay deployment. Regions facing infrastructure limitations are increasingly leveraging portable, battery-powered devices to bridge diagnostic gaps.

Asia-Pacific is witnessing some of the fastest growth rates globally, fueled by large patient populations and proactive government initiatives focused on disease surveillance. Economic growth in key markets has led to enhanced healthcare spending, while innovative payment models-such as subscription-based reagent plans-are unlocking access in mid-tier hospitals and clinics. Additionally, collaborations with local manufacturers are reducing costs and expediting market entry for new assays.

Uncovering Strategic Moves of Leading Players Driving Innovation in Point of Care Molecular Diagnostics Through Partnerships Mergers and Product Development

Leading industry participants are prioritizing strategic collaborations and acquisitions to broaden their point of care molecular diagnostics portfolios. Major diagnostic developers are forging partnerships with specialty reagent producers to co-develop proprietary assay chemistries and streamline supply chains. Simultaneously, a number of players have announced bolt-on acquisitions of software analytics firms to elevate data integration capabilities across decentralized testing networks.

On the innovation front, several organizations are piloting next-generation sequencing modules that can be tethered to mobile workstations, thereby bringing comprehensive genomic profiling to outpatient settings. Other companies are doubling down on isothermal amplification technology, aiming to deliver low-cost, high-throughput solutions amenable to field deployment in emerging markets. Across the board, differentiated assay sensitivity and specificity have become key competitive levers.

Moreover, an increasing emphasis on digital health has prompted diagnostic vendors to bundle connectivity services, offering cloud-based result management and remote quality-control dashboards. This shift is reshaping go-to-market strategies as customers demand turnkey solutions that encompass hardware, consumables, and software under unified service agreements.

Formulating Actionable Recommendations for Industry Leaders to Capitalize on Opportunities in Point of Care Molecular Diagnostics and Enhance Competitive Advantage

To capitalize on the growing demand for rapid molecular testing, industry leaders should invest in flexible platform architectures that support modular assay expansion. By designing systems capable of accommodating a wide range of reagent cartridges, organizations can swiftly respond to emerging pathogen threats and shifting clinical priorities. Equally important is the cultivation of strategic alliances with reagent manufacturers to ensure a reliable supply of high-quality chemistries.

Furthermore, aligning product development roadmaps with evolving regulatory frameworks and reimbursement pathways will expedite market access. Cross-functional task forces that include regulatory experts, clinical liaisons, and health economics professionals can proactively address compliance requirements and articulate value propositions to payers. In parallel, establishing training programs and remote support capabilities will enhance user adoption and minimize operator errors in decentralized environments.

Finally, enhancing supply chain resilience through the localization of key manufacturing processes and the creation of regional distribution hubs will mitigate the impact of future trade disruptions. Coupling these efforts with data-driven demand forecasting tools will optimize inventory levels and reduce lead times. By adopting these measures, decision-makers can secure a competitive edge while delivering reliable point of care diagnostics to a broad spectrum of end users.

Detailing the Rigorous Research Methodology Underpinning the Analysis for Comprehensive and Reliable Point of Care Molecular Diagnostics Insights

This analysis is grounded in a rigorous research framework that combines in-depth primary interviews with senior executives, laboratory directors, and clinical end users across multiple geographies. These conversations provided first-hand insights into adoption drivers, technology preferences, and operational challenges specific to point of care molecular applications.

Secondary research complemented these qualitative findings by drawing on peer-reviewed publications, regulatory filings, and corporate release documents. Data from industry whitepapers and public health agency reports were triangulated against proprietary databases to validate trends and ensure consistency. Each data point underwent cross-verification through multiple sources to maintain accuracy and objectivity.

Our segmentation approach aligns product types, technology modalities, clinical applications, and end user categories to deliver a nuanced understanding of market dynamics. Regional analyses were informed by economic indicators, healthcare spending patterns, and local regulatory landscapes. Key performance metrics and thematic insights were further tested through scenario planning exercises to assess resilience under varying market conditions.

Quality control measures-including independent peer reviews, editorial audits, and methodological sanity checks-ensure that findings meet the highest standards of reliability. The resulting perspectives offer stakeholders a robust foundation for strategic decision-making and informed investment in point of care molecular diagnostics.

Concluding Perspectives on the Transformative Potential and Strategic Imperatives of Point of Care Molecular Diagnostics in Modern Healthcare

Point of care molecular diagnostics stands at the intersection of technological innovation, clinical necessity, and economic pragmatism. As platforms become more compact, user friendly, and digitally connected, they have the potential to redefine diagnostic workflows and enhance patient outcomes across diverse care settings.

Industry participants must remain vigilant in adapting to shifting regulatory requirements, supply chain challenges, and evolving reimbursement landscapes. By embracing strategic partnerships, investing in modular architectures, and aligning closely with clinical stakeholders, organizations can harness the transformative power of rapid molecular testing. Ultimately, those who proactively integrate these solutions into healthcare delivery models will lead the migration toward faster, more personalized care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Point of Care Molecular Diagnostics Market, by Product Type

  • 8.1. Instruments
  • 8.2. Reagents & Kits
  • 8.3. Software

9. Point of Care Molecular Diagnostics Market, by Technology

  • 9.1. Genetic Sequencing-based
  • 9.2. Hybridization-based
  • 9.3. Isothermal Nucleic Acid Amplification Technology (INAAT)
  • 9.4. Microarray-based
  • 9.5. PCR-based

10. Point of Care Molecular Diagnostics Market, by Application

  • 10.1. Cardiology
  • 10.2. Genetic Testing
    • 10.2.1. Carrier Screening
    • 10.2.2. Newborn Screening
    • 10.2.3. Prenatal Testing
  • 10.3. Infectious Disease
    • 10.3.1. Gastrointestinal Infections
    • 10.3.2. Respiratory Infections
    • 10.3.3. Sexually Transmitted Infections
    • 10.3.4. Tropical Diseases
  • 10.4. Oncology
    • 10.4.1. Liquid Biopsy
    • 10.4.2. Mutation Profiling
    • 10.4.3. Oncogene Panel

11. Point of Care Molecular Diagnostics Market, by End User

  • 11.1. Clinics
  • 11.2. Diagnostic Laboratories
  • 11.3. Home Care Settings
  • 11.4. Hospitals

12. Point of Care Molecular Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Point of Care Molecular Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Point of Care Molecular Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Point of Care Molecular Diagnostics Market

16. China Point of Care Molecular Diagnostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. ACON LABS INC.
  • 17.7. Becton, Dickinson and Company
  • 17.8. Binx Health, inc.
  • 17.9. bioMerieux SA
  • 17.10. Cardinal Health, Inc.
  • 17.11. Chembio Diagnostics Inc.
  • 17.12. Co-Diagnostics, Inc.
  • 17.13. Danaher Corporation
  • 17.14. DiaSorin S.p.A
  • 17.15. EKF Diagnostics Holdings
  • 17.16. FHoffmann-La Roche AG
  • 17.17. Genomadix Inc. by LuminUltra Technologies Ltd.
  • 17.18. Henry Schein, Inc.
  • 17.19. Meridian Bioscience, Inc.
  • 17.20. Novartis AG
  • 17.21. OraSure Technologies, Inc.
  • 17.22. Pfizer, Inc.
  • 17.23. QIAGEN N.V.
  • 17.24. Quidel Corporation
  • 17.25. SD Biosensor
  • 17.26. Sekisui Diagnostics
  • 17.27. SHUWEN BIOTECH CO., LTD
  • 17.28. Siemens Healthineers AG
  • 17.29. Sysmex Corporation
  • 17.30. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC SEQUENCING-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC SEQUENCING-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC SEQUENCING-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEWBORN SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEWBORN SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TROPICAL DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TROPICAL DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TROPICAL DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MUTATION PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MUTATION PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MUTATION PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOGENE PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOGENE PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOGENE PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 166. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 190. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 198. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 199. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)